3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Neoplasms
8
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Urinary Bladder Neoplasms
5
Leukemia, Myeloid, Acute
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Mouth Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Ureteral Neoplasms
2
Stomatitis
2
Recurrence
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Brain Neoplasms
2
Adenocarcinoma
2
Interventions
Paclitaxel
6
Doxorubicin
6
Gemcitabine
4
Bevacizumab
4
pembrolizumab
3
pazopanib
3
durvalumab
3
Sorafenib
3
Docetaxel
3
trebananib
2
spartalizumab
2
cemiplimab
2
brostallicin
2
Propranolol
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Imatinib Mesylate
2
Ifosfamide
2
Carboplatin
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trastuzumab duocarmazine
1
temsirolimus
1
talimogene laherparepvec
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hemangiosarcoma
×
Standard of Care
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled